Mayo Lung Cancer Project: Status report.

R. Fontana,D. Sanderson,L. Woolner,W. E. Miller,P. E. Bernatz,W. Payne,W. Taylor

Abstract:

What problem does this paper attempt to address?

Molecular Diagnosis of Nasopharyngeal Carcinoma: Past and Future

Cheng-Lung Hsu,Yu-Sun Chang,Hsin-Pai Li

DOI: https://doi.org/10.1016/j.bj.2024.100748

IF: 5.5

2024-05-26

Biomedical Journal

Abstract:Nasopharyngeal carcinoma (NPC) is a malignant tumor originated from the nasopharynx epithelial cells and has been linked with Epstein-Barr virus (EBV) infection, dietary habits, environmental and genetic factors. It is a common malignancy in Southeast Asia, especially with gender preference among men. Due to its non-specific symptoms, NPC is often diagnosed at a late stage. Thus, the molecular diagnosis of NPC plays a crucial role in early detection, treatment selection, disease monitoring, and prognosis prediction. This review aims to provide a summary of the current state and the latest emerging molecular diagnostic techniques for NPC, including EBV-related biomarkers, gene mutations, liquid biopsy, and DNA methylation. Challenges and potential future directions of NPC molecular diagnosis will be discussed.

biochemistry & molecular biology,medicine, research & experimental
Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options

Zheran Liu,Ye Chen,Yonglin Su,Xiaolin Hu,Xingchen Peng

DOI: https://doi.org/10.3389/fonc.2021.635737

IF: 4.7

2021-11-29

Frontiers in Oncology

Abstract:Nasopharyngeal carcinoma (NPC) is a severe malignancy arising from the nasopharyngeal epithelium and is southern China’s third most common cancer. With the advancement of treatment methods, early-stage NPC patients usually have a better prognosis and more prolonged survival period than those with other malignant tumors. Most treatment failures are due to distant metastasis or a locally advanced stage of NPC in the initial diagnosis. In addition, approximately 10% of patients develop local recurrence, and 10%–20% of patients experience distant metastasis after treatment. These patients have a poor prognosis, with a median survival of only approximately 10–15 months. In the rapid development of treatment options, the efficacy and safety of some treatments have been validated and approved for first-line treatment, while those of other treatments remain unclear. The present study aims to provide a comprehensive overview of recent advances in NPC treatment and explain the various therapeutic possibilities in treating locally advanced, recurrent, and metastatic NPC patients.

oncology
Nasopharyngeal carcinoma: an evolving paradigm

Kenneth C. W. Wong,Edwin P. Hui,Kwok-Wai Lo,Wai Kei Jacky Lam,David Johnson,Lili Li,Qian Tao,Kwan Chee Allen Chan,Ka-Fai To,Ann D. King,Brigette B. Y. Ma,Anthony T. C. Chan

DOI: https://doi.org/10.1038/s41571-021-00524-x

IF: 78.8

2021-06-30

Nature Reviews Clinical Oncology

Abstract:The past three decades have borne witness to many advances in the understanding of the molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus (EBV)-associated cancer endemic to southern China, southeast Asia and north Africa. In this Review, we provide a comprehensive, interdisciplinary overview of key research findings regarding NPC pathogenesis, treatment, screening and biomarker development. We describe how technological advances have led to the advent of proton therapy and other contemporary radiotherapy approaches, and emphasize the relentless efforts to identify the optimal sequencing of chemotherapy with radiotherapy through decades of clinical trials. Basic research into the pathogenic role of EBV and the genomic, epigenomic and immune landscape of NPC has laid the foundations of translational research. The latter, in turn, has led to the development of new biomarkers and therapeutic targets and of improved approaches for individualizing immunotherapy and targeted therapies for patients with NPC. We provide historical context to illustrate the effect of these advances on treatment outcomes at present. We describe current preclinical and clinical challenges and controversies in the hope of providing insights for future investigation.

oncology
Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

Juan Jose Juarez-Vignon Whaley,Michelle Afkhami,Sagus Sampath,Arya Amini,Diana Bell,Victoria M. Villaflor

DOI: https://doi.org/10.1007/s11864-023-01083-2

2023-05-06

Current Treatment Options in Oncology

Abstract:Nasopharyngeal carcinoma (NPC) is a rare malignancy, endemic in China, that is commonly diagnosed in locally advanced scenarios. Its pathogenesis is strongly associated with Epstein-Barr virus (EBV), an infection for which measuring EBV plasma DNA levels has helped as a prognostic factor guiding treatment options, including a stronger treatment in those with high titers. Additionally, tobacco and alcohol are often implicated in EBV-negative patients. The local disease is treated with radiotherapy alone, preferentially intensity modulated radiotherapy. For locally advanced disease, the backbone treatment is concurrent chemoradiotherapy with the ongoing research dilemma being adding adjuvant chemotherapy or induction chemotherapy. The ongoing research is focused not only on identifying patients that will benefit from adjuvant or induction chemotherapy, but also on identifying the best chemotherapeutic regimen, regimen alternatives to diminish toxicity, the role that immune checkpoint inhibitors play, and the use of molecularly guided treatment targeting patients with NPC whether driven by EBV or tobacco and alcohol. Knowing the precise oncogenesis of NPC not only offers a better understanding of the role that EBV plays in this tumor but also helps create targeted therapies that could potentially block important pathways such as the NF-κB pathway. Much is yet to be done, but the prognosis and management of NPC patients have changed drastically, offering precise treatment methods and excellent control of the disease, even in locally advanced scenarios.

oncology
Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma

Yuanbo Kang,Weihan He,Caiping Ren,Jincheng Qiao,Qiuyong Guo,Jingyu Hu,Hongjuan Xu,Xingjun Jiang,Lei Wang

DOI: https://doi.org/10.1038/s41392-020-00340-2

IF: 39.3

2020-10-23

Signal Transduction and Targeted Therapy

Abstract:Abstract Nasopharyngeal carcinoma (NPC) is a malignant epithelial carcinoma of the head and neck region which mainly distributes in southern China and Southeast Asia and has a crucial association with the Epstein–Barr virus. Based on epidemiological data, both incidence and mortality of NPC have significantly declined in recent decades grounded on the improvement of living standard and medical level in an endemic region, in particular, with the clinical use of individualized chemotherapy and intensity-modulated radiotherapy (IMRT) which profoundly contributes to the cure rate of NPC patients. To tackle the challenges including local recurrence and distant metastasis in the current NPC treatment, we discussed the implication of using targeted therapy against critical molecules in various signal pathways, and how they synergize with chemoradiotherapy in the NPC treatment. Combination treatment including targeted therapy and IMRT or concurrent chemoradiotherapy is presumably to be future options, which may reduce radiation or chemotherapy toxicities and open new avenues for the improvement of the expected functional outcome for patients with advanced NPC.

biochemistry & molecular biology,cell biology
Current Status and Future Perspectives about Molecular Biomarkers of Nasopharyngeal Carcinoma

Pui Yan Siak,Alan Soo-Beng Khoo,Chee Onn Leong,Boon-Peng Hoh,Shiau-Chuen Cheah

DOI: https://doi.org/10.3390/cancers13143490

2021-07-12

Abstract:Nasopharyngeal carcinoma (NPC) is an epithelial malignancy that shows a remarkable ethnic and geographical distribution. It is one of the major public health problems in some countries, especially Southern China and Southeast Asia, but rare in most Western countries. Multifactorial interactions such as Epstein-Barr virus infection, individual's genetic susceptibility, as well as environmental and dietary factors may facilitate the pathogenesis of this malignancy. Late presentation and the complex nature of the disease have led it to become a major cause of mortality. Therefore, an effective, sensitive, and specific molecular biomarker is urgently needed for early disease diagnosis, prognosis, and prediction of metastasis and recurrence after treatment. In this review, we discuss the recent research status of potential biomarker discovery and the problems that need to be explored further for better NPC management. By studying the aberrant pattern of these candidate biomarkers that promote NPC development and progression, we are able to understand the complexity of this malignancy better, hence positing our stands better towards strategies that may provide a way forward to the discovery of more reliable and specific biomarkers for diagnosis and targeted therapeutic development.
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Pui Yan Siak,Win Sen Heng,Sharon Siew Hoon Teoh,Yu Yu Lwin,Shiau-Chuen Cheah

DOI: https://doi.org/10.1186/s12967-023-04673-8

2023-11-06

Abstract:Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with high propensity for lymphatic spread and distant metastasis. It is prominent as an endemic malignancy in Southern China and Southeast Asia regions. Studies on NPC pathogenesis mechanism in the past decades such as through Epstein Barr Virus (EBV) infection and oncogenic molecular aberrations have explored several potential targets for therapy and diagnosis. The EBV infection introduces oncoviral proteins that consequently hyperactivate many promitotic pathways and block cell-death inducers. EBV infection is so prevalent in NPC patients such that EBV serological tests were used to diagnose and screen NPC patients. On the other hand, as the downstream effectors of oncogenic mechanisms, the promitotic pathways can potentially be exploited therapeutically. With the apparent heterogeneity and distinct molecular aberrations of NPC tumor, the focus has turned into a more personalized treatment in NPC. Herein in this comprehensive review, we depict the current status of screening, diagnosis, treatment, and prevention in NPC. Subsequently, based on the limitations on those aspects, we look at their potential improvements in moving towards the path of precision medicine. The importance of recent advances on the key molecular aberration involved in pathogenesis of NPC for precision medicine progression has also been reported in the present review. Besides, the challenge and future outlook of NPC management will also be highlighted.
Novel therapy for nasopharyngeal carcinoma--where are we

Janice Tsang,Victor H F Lee,Dora L W Kwong

DOI: https://doi.org/10.1016/j.oraloncology.2014.01.002

Abstract:Nasopharyngeal carcinoma (NPC) is endemic in Southern China, and the South-East Asia including Hong Kong. We still see patients recur after primary treatment with radiotherapy or chemo-irradiation. Management of nasopharyngeal carcinoma remains one of the biggest clinical challenges. There have been breakthroughs in early detection, diagnosis, multi-modality treatment and also disease monitoring for NPC. Systemic treatment has been crucial to the management of locally advanced or metastatic NPC. With the advent of molecular targeted therapy and personalized medicine, novel therapies based on molecular targets of NPC have become the focus of research and development over the last decade. Furthermore, as NPC is tightly associated with the Epstein-Barr virus (EBV) infection, the role of tumor-associated viral antigens in NPC renders it an appealing candidate for cellular immunotherapy. This is a review of recent evolving concerted efforts and the success from our translational research with focus of the recent systemic novel targeted therapies including the potential role of immunotherapy which may offer further clinical benefit to our patients living with NPC. The scientific basis and latest published results of the relevant clinical trials are highlighted, demonstrating the ongoing battle against NPC is indeed one of the most fascinating successes in head and neck oncology.
Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies

Luvita Suryani,Hazel P. Y. Lee,Wei Keat Teo,Zhi Kang Chin,Kwok Seng Loh,Joshua K. Tay

DOI: https://doi.org/10.3390/cancers16050918

2024-02-24

Cancers

Abstract:Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV) driven malignancy arising from the nasopharyngeal epithelium. Current treatment strategies depend on the clinical stage of the disease, including the extent of the primary tumour, the extent of nodal disease, and the presence of distant metastasis. With the close association of EBV infection with NPC development, EBV biomarkers have shown promise in predicting treatment outcomes. Among the omic technologies, RNA and miRNA signatures have been widely studied, showing promising results in the research setting to predict treatment response. The transformation of radiology images into measurable features has facilitated the use of radiomics to generate predictive models for better prognostication and treatment selection. Nonetheless, much of this work remains in the research realm, and challenges remain in clinical implementation.

oncology
Genetic and epigenetic landscape of nasopharyngeal carcinoma

Wei Dai,Hong Zheng,Arthur Kwok Leung Cheung,Maria Li Lung

DOI: https://doi.org/10.21037/cco.2016.03.06

Abstract:Nasopharyngeal carcinoma (NPC) is a unique epithelial malignancy that shows a remarkable geographical and ethic distribution. Multiple factors including predisposing genetic factors, environmental carcinogens, and Epstein-Barr virus (EBV) infection contribute to the accumulation of genetic and epigenetic alterations leading to NPC development. Emerging technologies now allow us to detailedly characterize and understand cancer genomes. Genome-wide studies show that typically NPC tumors are characterized as having comparatively low mutation rates, widespread hypermethylation, and frequent copy number alterations and chromosome abnormalities. In this review, we provide an updated overview of the genetic and epigenetic aberrations that likely drive nasopharyngeal tumor development and progression. We integrate the previous knowledge and novel findings from whole-exome sequencing (WES) and methylome studies in NPC, and further discuss the potential use of these findings to identify biomarkers for NPC diagnosis and prognosis.
Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies

Chenxi Xia,Jia Zhao,Yu Huang,Hongbin Miao,Feipeng Zhao

DOI: https://doi.org/10.3389/fonc.2024.1331064

IF: 4.7

2024-05-28

Frontiers in Oncology

Abstract:Nasopharyngeal carcinoma (NPC) is a highly prevalent head and neck malignancy in southern China frequently diagnosed at advanced stages owing to subtle early symptoms and associated metastasis. Angiogenesis emerges as a pivotal factor in NPC progression, with numerous angiogenesis-related factors showing aberrant expression and contributing to increased neovascularization within NPC tumors. These abnormal vessels not only nourish tumor growth but also facilitate metastasis, culminating in unfavorable patient outcomes. Multiple studies have demonstrated the applicability of various imaging techniques for assessing angiogenesis in NPC tumors, thus serving as a foundation for personalized treatment strategies and prognostic assessments. Anti-angiogenic therapies have exhibited significant potential for inhibiting NPC angiogenesis and exerting anti-tumor effects. To enhance efficacy, anti-angiogenic drugs are frequently combined with other treatment modalities to synergistically enhance anti-tumor effects while mitigating the side effects associated with single-agent therapies, consequently improving patient prognosis. Identifying the potential mechanisms and key targets underlying NPC angiogenesis and exploring more effective detection and treatment approaches holds promise for shaping the future of NPC diagnosis, treatment, and prognosis, thereby offering new avenues and perspectives for research and clinical practice.

oncology
Paraffinoma of the Periorbit—A Challenge for the Oculoplastic Surgeon

C. Hintschich,C. Beyer-Machule,F. Stefani

DOI: https://doi.org/10.1097/00002341-199503000-00007

1995-03-01

Ophthalmic Plastic and Reconstructive Surgery

Abstract:Summary Five patients with a history of sinus surgery with nasal packing and postoperative hemorrhage developed nontender, firm tumors of the periorbit. There was no spontaneous regression. Surgical excision was difficult due to diffuse cellular infiltration and intracutaneous deposits, requiring re-operations in all patients. Histology showed a marked lipogranulomatous reaction to dispersed lipid material with fibrosis. Paraffinoma is a known complication of paraffin injection in dermatology and cosmetic surgery. Reports of it in the ophthalmic literature are rare. This series documents a late complication of sinus surgery, very probably due to the intraoperative nasal packing with paraffin-containing ointments.
Investigational drugs for nasopharyngeal carcinoma

Brigette B.Y.,Edwin P Hui,Anthony T.C. Chan,Brigette B.Y. Ma

DOI: https://doi.org/10.1080/13543784.2017.1324568

2017-05-08

Expert Opinion on Investigational Drugs

Abstract:INTRODUCTION: Nasopharyngeal carcinoma (NPC) is endemic to Southern China and Asia and is etiologically associated with the Epstein Barr virus (EBV). Whole exome and genome sequencing (WES, WGS) studies of NPC have reported several actionable therapeutic targets, and that the mutational load of NPC maybe comparable to that of squamous head and neck cancer. These unique biological characteristics have been exploited as potential targets and a wide range of investigational drugs are being investigated in clinical trials. Area covered: This review focused on the latest clinical development of the most promising classes of investigational agents in the treatment of advanced NPC. These include inhibitors of tumor angiogenesis, kinase signaling pathways and immunotherapy. Expert opinion: Checkpoint inhibitors and EBV-specific T-cell therapy have shown promising activity in early phase clinical trials, and are being further evaluated in randomized studies. For patients whose tumors express genetic alterations that are known to predict response to kinase inhibitors, novel trial designs such as an 'Umbrella' study may be considered given the abundance of targeted agents that are now available for clinical evaluation. It is envisioned that regulatory approval for new drugs for advanced NPC will occur in the near future.

pharmacology & pharmacy
[Thrombolytic therapy of ischemic heart disease].

K. Kanmatsuse,K. Nagao,K. Kikushima,K. Shioiri

1997-09-10

Abstract:
Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high-throughput omics (Review)

S. Pan,Hai-bin Chen,Yu-Shuai Han,Shan-Qiang Zhang,Jicheng Li,Sixian Liang

DOI: https://doi.org/10.3892/ijo.2021.5188

2021-02-15

International Journal of Oncology

Abstract:As a malignant tumor type, nasopharyngeal carcinoma (NPC) is characterized by distinct geographical, ethnic and genetic differences; presenting a major threat to human health in many countries, especially in Southern China. At present, no accurate and effective methods are available for the early diagnosis, efficacious evaluation or prognosis prediction for NPC. As such, a large number of patients have locoregionally advanced NPC at the time of initial diagnosis. Many patients show toxic reactions to overtreatment and have risks of cancer recurrence and distant metastasis owing to insufficient treatment. To solve these clinical problems, high-throughput '-omics' technologies are being used to screen and identify specific molecular biomarkers for NPC. Because of the lack of comprehensive descriptions regarding NPC biomarkers, the present study summarized the research progress that has been made in recent years to discover NPC biomarkers, highlighting the existing problems that require exploration. In view of the lack of authoritative reports at present, study design factors that affect the screening of biomarkers are also discussed here and prospects for future research are proposed to provide references for follow-up studies of NPC biomarkers.

Medicine
Epidemiology of nasopharyngeal carcinoma: current insights and future outlook

Zhi Yi Su,Pui Yan Siak,Yu Yu Lwin,Shiau-Chuen Cheah

DOI: https://doi.org/10.1007/s10555-024-10176-9

2024-03-03

Cancer and Metastasis Reviews

Abstract:Nasopharyngeal carcinoma (NPC) is characterised by its remarkable geographical and ethnic distribution. The interplay between genetic susceptibility, environmental exposures, and Epstein–Barr virus (EBV) infections is indicated in the development of NPC. Exposure to tobacco smoking, dietary factors, and inhalants has been associated with the risk of NPC. Genetic association studies have revealed NPC-associated susceptibility loci, including genes involved in immune responses, xenobiotic metabolism, genome maintenance, and cell cycle regulation. EBV exposure timing and strain variation might play a role in its carcinogenicity, although further investigations are required. Other factors including medical history and oral hygiene have been implicated in NPC. Prevention strategies, including primary prevention and secondary prevention through early detection, are vital in reducing mortality and morbidity of NPC. The current review discusses the global and regional distribution of NPC incidences, the risk factors associated with NPC, and the public health implications of these insights. Future investigations should consider international, large-scale prospective studies to elucidate the mechanisms underlying NPC pathogenesis and develop individualized interventions for NPC.

oncology
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Huai Liu,Ling Tang,Yanxian Li,Wenji Xie,Ling Zhang,Hailin Tang,Tengfei Xiao,Hongmin Yang,Wangning Gu,Hui Wang,Pan Chen

DOI: https://doi.org/10.1186/s12943-023-01928-2

IF: 37.3

2024-01-25

Molecular Cancer

Abstract:The incidence of nasopharyngeal carcinoma (NPC) exhibits significant variations across different ethnic groups and geographical regions, with Southeast Asia and North Africa being endemic areas. Of note, Epstein-Barr virus (EBV) infection is closely associated with almost all of the undifferentiated NPC cases. Over the past three decades, radiation therapy and chemotherapy have formed the cornerstone of NPC treatment. However, recent advancements in immunotherapy have introduced a range of promising approaches for managing NPC. In light of these developments, it has become evident that a deeper understanding of the tumor microenvironment (TME) is crucial. The TME serves a dual function, acting as a promoter of tumorigenesis while also orchestrating immunosuppression, thereby facilitating cancer progression and enabling immune evasion. Consequently, a comprehensive comprehension of the TME and its intricate involvement in the initiation, progression, and metastasis of NPC is imperative for the development of effective anticancer drugs. Moreover, given the complexity of TME and the inter-patient heterogeneity, personalized treatment should be designed to maximize therapeutic efficacy and circumvent drug resistance. This review aims to provide an in-depth exploration of the TME within the context of EBV-induced NPC, with a particular emphasis on its pivotal role in regulating intercellular communication and shaping treatment responses. Additionally, the review offers a concise summary of drug resistance mechanisms and potential strategies for their reversal, specifically in relation to chemoradiation therapy, targeted therapy, and immunotherapy. Furthermore, recent advances in clinical trials pertaining to NPC are also discussed.

oncology,biochemistry & molecular biology
Chinese Expert Consensus on Diagnosis and Treatment of Nasopharyngeal Carcinoma: Evidence from Current Practice and Future Perspectives

Jinyi Lang,Chaosu Hu,Taixiang Lu,Jianji Pan,Tongyu Lin

DOI: https://doi.org/10.2147/cmar.s197544

2019-01-01

Cancer Management and Research

Abstract:Nasopharyngeal carcinoma (NPC) is a rare type of head and neck cancer, with a higher incidence reported only in Southeast Asia and Northern Africa. Owing to the rarity of NPC occurrence, no internationally accepted consensus or guideline for its diagnosis and treatment is available. Based on the current evidences and practices, the Chinese experts on multidisciplinary diagnosis and treatment of NPC were designated to develop a national consensus for the treatment strategy of NPC. In this consensus, we report the development for improving the treatment efficacy and quality of life of NPC patients in China. The consensus also describes and recommends the role of multidisciplinary management approach in the management of NPC. A multidisciplinary team should include experts from different domains who can cater to the individualized needs of patients with NPC in a much more efficient manner. In addition, the team may also play a key role in developing guiding principles for future research, contributing to the improvement in the management of NPC.
Nasopharyngeal Carcinoma with Particular Characteristics: Case Report.

YY Lu,P Shen,GP Ren

2002-01-01

Abstract:Nasopharyngeal carcinoma (NPC) is a high morbidity tumor of otorhinolaryngology. The usual clinical manifestations are well known by the specialists. But the bizarre and confusing nature of NPC has misled clinicians and contributed to delayed diagnosis. Recently our department treated a case with unusual nasopharyngeal carcinoma.
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma

Kelvin Yan,Darren Wt Lim,Brigette B.B.Y. Ma

DOI: https://doi.org/10.1080/13543784.2024.2401910

2024-09-21

Expert Opinion on Investigational Drugs

Abstract:Introduction Nasopharyngeal carcinoma (NPC) remains an endemic disease in certain parts of the world, with many patients presenting with advanced disease on diagnosis. Chemotherapy had remained the standard of care with minimal progress made until recent years. This review aims to provide an overview of recent significant breakthroughs and up-and-coming novel strategies in treating this deadly disease.

pharmacology & pharmacy

Mayo Lung Cancer Project: Status report.

Molecular Diagnosis of Nasopharyngeal Carcinoma: Past and Future

Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options

Nasopharyngeal carcinoma: an evolving paradigm

Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma

Current Status and Future Perspectives about Molecular Biomarkers of Nasopharyngeal Carcinoma

Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

Novel therapy for nasopharyngeal carcinoma--where are we

Precision Medicine for Nasopharyngeal Cancer—A Review of Current Prognostic Strategies

Genetic and epigenetic landscape of nasopharyngeal carcinoma

Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies

Paraffinoma of the Periorbit—A Challenge for the Oculoplastic Surgeon

Investigational drugs for nasopharyngeal carcinoma

[Thrombolytic therapy of ischemic heart disease].

Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high-throughput omics (Review)

Epidemiology of nasopharyngeal carcinoma: current insights and future outlook

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Chinese Expert Consensus on Diagnosis and Treatment of Nasopharyngeal Carcinoma: Evidence from Current Practice and Future Perspectives

Nasopharyngeal Carcinoma with Particular Characteristics: Case Report.

Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma